* Zura Bio Ltd ZURA.OQ ZURA.O is expected to show no
change in
quarterly revenue when it reports results on August 12
(estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for Zura Bio Ltd is for a
loss
of 15 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Zura Bio
Ltd is
$16.00, above its last closing price of $3.54.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.23 -0.02 Beat 91.4
Dec. 31 0001 -0.23 -0.19 Beat 17.5
Jan. 1 0001 -0.25 -0.25 -0.18 Beat 27.4
Jun. 30 2023 -0.23 -0.25 -1.31 Missed -431.1
This summary was machine generated August 9 at 18:54 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)